|10th September 2020||Jennifer K. Simpson||1,000||Open or private purchase||$2.74||$2,737.10|
|1st September 2020||Jennifer K. Simpson||2,424||Open or private purchase||$0.00|
|8th May 2020||Marco Taglietti||6,000||Conversion of derivative||$0.00|
|8th May 2020||Barbra Keck||6,800||Conversion of derivative||$0.00|
|8th May 2020||John Purpura||6,500||Conversion of derivative||$0.00|
|8th May 2020||Roger G Phd Stoll||9,300||Conversion of derivative||$0.00|
|8th May 2020||William Dodge Rueckert||6,000||Conversion of derivative||$0.00|
|8th May 2020||Jennifer K. Simpson||14,700||Conversion of derivative||$0.00|
|6th May 2020||Barbra Keck||6,040||Grant/award etc.||$0.00|
|6th May 2020||John Purpura||6,613||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes CHEMOSAT and Melphalan Hydrochloride for Injection.